<div class="white-sheet">
    <div class="content-slide">


     
        

        <div class="title-bar red"></div>

		<div class="wrapper slide-1-1">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                <div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>		
			</div>

			<div class="slide-title red two-line">
				Immunosuppressive therapy: horse versus rabbit<br />
                antithymocyte globulin
			</div>


			<div class="content-container">

                <ul>
                    <li><span>These data indicate that h-ATG is superior to r-ATG<sup>1â€“4</sup></span></li>
                    <li><span>h-ATG is available as a licensed medicine in the USA but has to be obtained from specialist importers when used in Europe, where r-ATG predominates<sup>5</sup></span></li>
                </ul>
				
				<table class="red">
					<tr>
						<th colspan="8">Studies comparing h-ATG/CsA and r-ATG/CsA as first-line therapy in severe aplastic anaemia</th>
					</tr>

					<tr class="odd" style="font-weight:bold">
						<td>Study (year)</td>
                        <td width="45">h-ATG, n</td>
                        <td width="45">r-ATG, n</td>
                        <td>h-ATG formulation</td>
                        <td>r-ATG formulation</td>
                        <td>h-ATG response, %</td>
                        <td>r-ATG response, %</td>
						<td>Outcome comparison<br /> between ATGs</td>
					</tr>

					<tr>
						<td>Zheng (2006)<sup>1</sup></td>
                        <td>47</td>
                        <td>32</td>
                        <td>Lymphoglobulin</td>
                        <td>Fresenius</td>
                        <td>78.7</td>
                        <td>53.2</td>
						<td>Comparative statistics<br /> not reported</td>
					</tr>

					<tr class="odd">
						<td>Atta (2010)<sup>2</sup></td>
                        <td>42</td>
                        <td>29</td>
                        <td>Lymphoglobulin</td>
                        <td>Thymoglobulin</td>
                        <td>59.5</td>
                        <td>34.5</td>
						<td>Difference at statistical significance (historical comparison)</td>
					</tr>

                    <tr>
                        <td>Afable (2011)<sup>3</sup></td>
                        <td>67</td>
                        <td>20</td>
                        <td>Atgam</td>
                        <td>Thymoglobulin</td>
                        <td>58</td>
                        <td>50</td>
                        <td>Difference not statistical significance (historical comparison)</td>
                    </tr>

                    <tr class="odd">
                        <td>Scheinberg (2011)<sup>4</sup></td>
                        <td>60</td>
                        <td>60</td>
                        <td>Atgam</td>
                        <td>Thymoglobulin</td>
                        <td>68</td>
                        <td>37</td>
                        <td>Statistically significant difference (direct comparison)</td>
                    </tr>


				</table>

			</div>

		</div>


        <div class="information-overlay overlay">
            
            <header>Immunosuppressive therapy: horse versus rabbit antithymocyte globulin<sup>6</sup></header>

            <ul>
                <li><span>Monoclonal antibodies have also been proposed as alternatives to conventional IST in severe aplastic anaemia</span>
                    <ul>
                        <li><span>Alemtuzumab: total response rate: 58% (survival in the prospective trial: 73%)</span></li>
                    </ul>
                </li>
            </ul>
            
          

        </div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
                <li class="navigateHref" data-navtarget="media/documents/module2/ZhengY-2006-ExpHematol-v34p826.pdf"><span>Zheng Y <i>et al. Experiment Hematol</i> 2006;34:826</span></li>
                <li class="navigateHref" data-navtarget="media/documents/module2/AttaE-2010-AnnHaematol-v89p851.pdf"><span>Atta EH <i>et al. Ann Hematol</i> 2010;89:851</span></li>
                <li class="navigateHref" data-navtarget="media/documents/module2/AfableM-2011-Haematologica-v96p1269.pdf"><span>Afable MG <i>et al. Haematologica</i> 2011;96:1269</span></li>
                <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2011-NEJM-v365p430.pdf"><span>Scheinberg P <i>et al. N Engl J Med</i> 2011;365:430</span></li>
                <li class="navigateHref" data-navtarget="media/documents/module2/NHSTreatmentAdvisoryGroupReport-2012.pdf"><span>NHS North East Treatment Advisory Group appraisal report. 2012. http://www.netag.nhs.uk/files/appraisal-reports/ATG%20for%20-adult-%20aplastic%20anaemia%20-%20NETAG%20appraisal%20report%20-%20Dec2012.pdf (accessed October 2013)</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/RisitanoAM-2010-BrJHaematol-v148p791.pdf"><span>Risitano AM <i>et al. Br J Haematol</i> 2010;148:791</span></li>
			</ol>

		</div>


          
   


    </div>
 </div>